Neuralink implants brain chip in first human
Neuralink, the brain-chip startup led by billionaire Elon Musk, has successfully implanted its first human patient, according to Musk's announcement on the social media platform X. The implant, part of Neuralink's ongoing efforts in developing brain-computer interfaces (BCIs), is reportedly showing promising results, particularly in detecting neuron spikes. Neurons, as described by the National Institute of Health, are crucial for transmitting electrical and chemical signals throughout the brain and body.
This significant milestone follows the U.S. Food and Drug Administration's clearance last year for Neuralink to conduct human trials. The company, which had been recruiting paralysis patients for the study, employs a robot for the surgical placement of the BCI implant. This implant focuses on the brain area responsible for the intention to move, aiming to enable individuals to control devices like a computer cursor or keyboard solely through thought.
Neuralink's approach involves "ultra-fine" threads within the implants for transmitting brain signals. Musk has revealed that the first product to emerge from this technology will be called "Telepathy". The startup's PRIME Study, a trial for its wireless BCI, is primarily focused on assessing the safety of both the implant and the surgical robot.
Despite these advancements, Neuralink has faced scrutiny and concerns over its safety protocols. Earlier this month, Reuters reported that the company was fined for breaching U.S. Department of Transportation rules regarding hazardous materials. Additionally, the company, valued at around $5 billion as of last June, has been under lawmakers' radar. Four U.S. legislators requested the Securities and Exchange Commission to investigate potential misleading claims by Musk about the technology's safety. This request followed reports of adverse effects, such as paralysis, seizures, and brain swelling, in animal trials involving monkeys.
As Neuralink progresses with its groundbreaking work in the realm of BCIs, the balance between innovation and safety remains a critical aspect under close observation.